

SCORE Search Results Details for Application 10552515 and Search Result 20080624_135912_us-10-552-515-1_copy_157_933.szm.rag.

Score Home	Retrieve Application	SCORE System	SCORE	Comments /
Page	List	Overview	FAQ	Suggestions

This page gives you Search Results detail for the Application 10552515 and Search Result 20080624_135912_us-10-552-515-1_copy_157_933.szm.rag.

[Go Back to previous page](#)

GenCore version 6.2.1

Copyright (c) 1993 - 2008 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: June 24, 2008, 15:35:29 ; Search time 326 Seconds
(without alignments)
1434.542 Million cell updates/sec

Title: US-10-552-515-1_COPY_157_933
Perfect score: 4123
Sequence: 1 QQDVQDGNTTVHYALLSASW.....SELSSHWTPTVTPKASQLQQ 777

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 3405708 seqs, 601879884 residues

Total number of hits satisfying chosen parameters: 936429

Minimum DB seq length: 8
Maximum DB seq length: 20

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_200711:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000:*
4: geneseqp2001:*
5: geneseqp2002:*
6: geneseqp2003a:*
7: geneseqp2003b:*

8: geneseqp2004a:*
 9: geneseqp2004b:*
 10: geneseqp2005:*
 11: geneseqp2006:*
 12: geneseqp2007:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query		Length	DB	ID	Description
		Match					
1	65	1.6		20	4	ABB37977	Abb37977 Peptide #
2	65	1.6		20	4	AAM31389	Aam31389 Peptide #
3	65	1.6		20	4	ABG52827	Abg52827 Human liv
4	65	1.6		20	4	AAM18857	Aam18857 Peptide #
5	65	1.6		20	5	ABG40906	Abg40906 Human pep
6	52	1.3		15	6	ABJ54930	Abj54930 151P3D4 c
7	52	1.3		15	6	ABJ55780	Abj55780 151P3D4 c
8	52	1.3		15	6	ABJ54446	Abj54446 151P3D4 c
9	52	1.3		15	6	ABJ56387	Abj56387 151P3D4 c
10	48	1.2		9	8	ADT77672	Adt77672 Splice va
11	48	1.2		15	6	ABJ55714	Abj55714 151P3D4 c
12	48	1.2		15	6	ABJ54418	Abj54418 151P3D4 c
13	48	1.2		15	6	ABJ54982	Abj54982 151P3D4 c
14	48	1.2		15	6	ABJ56325	Abj56325 151P3D4 c
15	47	1.1		15	6	ABJ56284	Abj56284 151P3D4 c
16	47	1.1		15	6	ABJ54968	Abj54968 151P3D4 c
17	47	1.1		15	6	ABJ54396	Abj54396 151P3D4 c
18	47	1.1		15	6	ABJ55784	Abj55784 151P3D4 c
19	47	1.1		20	4	AAB90144	Aab90144 Factor VI
20	47	1.1		20	5	AAM48068	Aam48068 RNA bindi
21	47	1.1		20	7	ABR82328	Abr82328 Clone AD
22	47	1.1		20	7	ABR82336	Abr82336 Factor X
23	46.5	1.1		18	2	AAR82864	Aar82864 N-termina
24	46	1.1		9	8	ADT77666	Adt77666 Splice va
25	46	1.1		15	5	ABJ14449	Abj14449 Human 125
26	46	1.1		15	5	ABJ14602	Abj14602 Human 125
27	46	1.1		15	5	ABJ14448	Abj14448 Human 125
28	46	1.1		15	5	ABJ14731	Abj14731 Human 125
29	46	1.1		15	8	ADL21968	Adl21968 125P5C8 p
30	46	1.1		15	8	ADL21686	Adl21686 125P5C8 p
31	46	1.1		15	8	ADL21839	Adl21839 125P5C8 p
32	46	1.1		15	8	ADL21685	Adl21685 125P5C8 p
33	45.5	1.1		20	6	ADD12327	Add12327 PDZ ligand
34	45	1.1		20	6	ADC15450	Adc15450 Human bre

35	45	1.1	20	6	ADC15451	Adc15451	Human bre
36	44	1.1	9	8	ADT77673	Adt77673	Splice va
37	44	1.1	13	2	AAW70925	Aaw70925	CDR3 of t
38	44	1.1	16	8	ADW68208	Adw68208	Rabbit an
39	44	1.1	16	8	ADO79153	Ado79153	Rabbit an
40	44	1.1	18	5	ABB78503	Abb78503	GAGP rela
41	44	1.1	18	8	ADU09291	Adu09291	Gum arabi
42	44	1.1	19	3	AAV79347	Aay79347	Equine in
43	44	1.1	19	5	ABB78401	Abb78401	Gum arabi
44	44	1.1	19	5	ABB78463	Abb78463	Gum arabi
45	44	1.1	19	5	ABB78465	Abb78465	Gum arabi

ALIGNMENTS

RESULT 1

ABB37977

ID ABB37977 standard; peptide; 20 AA.

XX

AC ABB37977;

XX

DT 04-FEB-2002 (first entry)

XX

DE Peptide #5483 encoded by human foetal liver single exon probe.

XX

KW Human; foetal liver; gene expression; single exon nucleic acid probe.

XX

OS Homo sapiens.

XX

PN WO200157277-A2.

XX

PD 09-AUG-2001.

XX

PF 30-JAN-2001; 2001WO-US000669.

XX

PR 04-FEB-2000; 2000US-0180312P.

PR 26-MAY-2000; 2000US-0207456P.

PR 30-JUN-2000; 2000US-00608408.

PR 03-AUG-2000; 2000US-00632366.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

XX

PA (MOLE-) MOLECULAR DYNAMICS INC.

XX

PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX

DR WPI; 2001-483447/52.

XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human fetal liver.
XX
PS Claim 27; SEQ ID NO 30612; 639pp + Sequence Listing; English.
XX
CC The invention relates to a single exon nucleic acid probe for measuring
CC human gene expression in a sample derived from human foetal liver. The
CC single exon nucleic acid probes may be used for predicting, measuring and
CC displaying gene expression in samples derived from human fetal liver. The
CC present sequence is a peptide encoded by a single exon nucleic acid probe
CC of the invention. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 AA;

Query Match 1.6%; Score 65; DB 4; Length 20;
Best Local Similarity 60.0%; Pred. No. 45;
Matches 12; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 437 IFQFVNIFYSSPVYIAFFKGR 456
: :||| || |:|||||
Db 1 LLKFVNAYSPIFYVAFFKGR 20

RESULT 2
AAM31389
ID AAM31389 standard; protein; 20 AA.
XX
AC AAM31389;
XX
DT 17-OCT-2001 (first entry)
XX
DE Peptide #5426 encoded by probe for measuring placental gene expression.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
KW genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.

PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 27; SEQ ID NO 31658; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP:
CC see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders
XX
SQ Sequence 20 AA;

Query Match 1.6%; Score 65; DB 4; Length 20;
Best Local Similarity 60.0%; Pred. No. 45;
Matches 12; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 437 IFQFVNIFYSSPVYIAFFKGR 456
: :||| || |:|||||
Db 1 LLKFVNAYSPIFYVAFFKGR 20

RESULT 3
ABG52827
ID ABG52827 standard; peptide; 20 AA.
XX
AC ABG52827;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver peptide, SEQ ID No 31475.
XX
KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.
XX
OS Homo sapiens.

XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human adult liver.
XX
PS Claim 27; SEQ ID NO 31475; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABG47348-ABG59930 represent human
CC liver single exon encoded peptides of the invention. Note: The sequence
CC information for this patent does not appear in the printed specification
CC but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 AA;

Query Match 1.6%; Score 65; DB 4; Length 20;
Best Local Similarity 60.0%; Pred. No. 45;
Matches 12; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 437 IFQFVNIFYSSPVYIAFFKGR 456
: :||| || |:|||||

Db 1 LLKFVNAYSPIFYVAFFKGR 20

RESULT 4

AAM18857

ID AAM18857 standard; protein; 20 AA.

XX

AC AAM18857;

XX

DT 12-OCT-2001 (first entry)

XX

DE Peptide #5291 encoded by probe for measuring cervical gene expression.

XX

KW Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer.

XX

OS Homo sapiens.

XX

PN WO200157278-A2.

XX

PD 09-AUG-2001.

XX

PF 30-JAN-2001; 2001WO-US000670.

XX

PR 04-FEB-2000; 2000US-0180312P.

PR 26-MAY-2000; 2000US-0207456P.

PR 30-JUN-2000; 2000US-00608408.

PR 03-AUG-2000; 2000US-00632366.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

XX

PA (MOLE-) MOLECULAR DYNAMICS INC.

XX

PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX

DR WPI; 2001-488901/53.

XX

PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human cervical epithelial cells.

XX

PS Claim 27; SEQ ID NO 23683; 487pp; English.

XX

CC The present invention relates to human single exon nucleic acid probes
CC (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC can be used to produce a single exon microarray, which can be used for
CC measuring human gene expression in a sample derived from human cervical
CC epithelial cells. By measuring gene expression, the probes are therefore

CC useful in grading and/or staging of diseases of the cervix, notably
CC cervical cancer. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 AA;

Query Match 1.6%; Score 65; DB 4; Length 20;
Best Local Similarity 60.0%; Pred. No. 45;
Matches 12; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 437 IFQFVNIFYSSPVYIAFFKGR 456
: :||| || |:|||||
Db 1 LLKFVNAYSPIFYVAFFKGR 20

RESULT 5
ABG40906
ID ABG40906 standard; peptide; 20 AA.
XX
AC ABG40906;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 30571.
XX
KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomatosis; Karagenen syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesia; pulmonary hypertension;
KW hyaline membrane disease.
XX
OS Homo sapiens.
XX
PN WO200186003-A2.
XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US000665.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

XX

PA (MOLE-) MOLECULAR DYNAMICS INC.

XX

PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX

DR WPI; 2002-114183/15.

XX

PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples.

XX

PS Claim 27; SEQ ID NO 30571; 634pp; English.

XX

CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of probes
CC ; the novel set of probes which hybridise at high stringency to a nucleic
CC acid expressed in the human lung; measuring gene expression in a sample
CC derived from human lung, comprising (a) contacting the array with a
CC collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of the
CC array; identifying exons in a eukaryotic genome, comprising (a)
CC algorithmically predicting at least one exon from genomic sequences of
CC the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene expression
CC analysis, and for identifying exons in a gene, particularly using human
CC lung derived mRNA and for the study of lung diseases such as asthma, lung
CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC histiocytosis, lymphangioliomyomatosis, pulmonary alveolar proteinosis,
CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC dyskinesia, pulmonary hypertension and hyaline membrane disease. The
CC present sequence is a peptide/protein encoded by a single exon probe of

CC the invention. Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 AA;

Query Match 1.6%; Score 65; DB 5; Length 20;
Best Local Similarity 60.0%; Pred. No. 45;
Matches 12; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 437 IFQFVNIFYSSPVYIAFFKGR 456
: :||| || |:|||||
Db 1 LLKFVNAYSPIFYVAFFKGR 20

RESULT 6
ABJ54930

ID ABJ54930 standard; peptide; 15 AA.
XX
AC ABJ54930;
XX
DT 16-OCT-2003 (first entry)
XX
DE 151P3D4 cancer gene related HLA peptide #12750.
XX
KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX
OS Homo sapiens.
XX
PN WO200283860-A2.
XX
PD 24-OCT-2002.
XX
PF 09-APR-2002; 2002WO-US011644.
XX
PR 10-APR-2001; 2001US-0282739P.
PR 25-APR-2001; 2001US-0286630P.
XX
PA (AGEN-) AGENSYS INC.
XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
DR WPI; 2003-167091/16.
XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or

PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.
XX
PS Claim 13; Page 287; 426pp; English.
XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoural or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention
XX
SQ Sequence 15 AA;

Query Match 1.3%; Score 52; DB 6; Length 15;
Best Local Similarity 60.0%; Pred. No. 7.3e+02;
Matches 9; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFGV 470
|||:| | |:
Db 1 RFVGFPDKKHKLYGV 15

RESULT 7
ABJ55780

ID ABJ55780 standard; peptide; 15 AA.
XX
AC ABJ55780;
XX
DT 16-OCT-2003 (first entry)
XX
DE 151P3D4 cancer gene related HLA peptide #13600.
XX
KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX
OS Homo sapiens.
XX
PN WO200283860-A2.
XX
PD 24-OCT-2002.
XX
PF 09-APR-2002; 2002WO-US011644.

XX
PR 10-APR-2001; 2001US-0282739P.
PR 25-APR-2001; 2001US-0286630P.
XX
PA (AGEN-) AGENSYS INC.
XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
DR WPI; 2003-167091/16.
XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.
XX
PS Claim 13; Page 303; 426pp; English.
XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoural or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention
XX
SQ Sequence 15 AA;

Query Match 1.3%; Score 52; DB 6; Length 15;
Best Local Similarity 60.0%; Pred. No. 7.3e+02;
Matches 9; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFGV 470
|||:| | |:|
Db 1 RFVGFPDKHKLYGV 15

RESULT 8
ABJ54446
ID ABJ54446 standard; peptide; 15 AA.
XX
AC ABJ54446;
XX
DT 16-OCT-2003 (first entry)
XX

DE 151P3D4 cancer gene related HLA peptide #12266.
XX
KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX
OS Homo sapiens.
XX
PN WO200283860-A2.
XX
PD 24-OCT-2002.
XX
PF 09-APR-2002; 2002WO-US011644.
XX
PR 10-APR-2001; 2001US-0282739P.
PR 25-APR-2001; 2001US-0286630P.
XX
PA (AGEN-) AGENSYS INC.
XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
DR WPI; 2003-167091/16.
XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.
XX
PS Claim 13; Page 278; 426pp; English.
XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention
XX
SQ Sequence 15 AA;

Query Match 1.3%; Score 52; DB 6; Length 15;
Best Local Similarity 60.0%; Pred. No. 7.3e+02;
Matches 9; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFGV 470
||||:| | |:|
Db 1 RFVGFPDKKHKLYGV 15

RESULT 9

ABJ56387

ID ABJ56387 standard; peptide; 15 AA.
XX
AC ABJ56387;
XX
DT 16-OCT-2003 (first entry)
XX
DE 151P3D4 cancer gene related HLA peptide #14207.
XX
KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX
OS Homo sapiens.
XX
PN WO200283860-A2.
XX
PD 24-OCT-2002.
XX
PF 09-APR-2002; 2002WO-US011644.
XX
PR 10-APR-2001; 2001US-0282739P.
PR 25-APR-2001; 2001US-0286630P.
XX
PA (AGEN-) AGENSYS INC.
XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
DR WPI; 2003-167091/16.
XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.
XX
PS Claim 13; Page 314; 426pp; English.
XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting

CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention
XX
SQ Sequence 15 AA;

Query Match 1.3%; Score 52; DB 6; Length 15;
Best Local Similarity 60.0%; Pred. No. 7.3e+02;
Matches 9; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLEFGV 470
|||:| | |:
Db 1 RFVGFPDKKHKLYGV 15

RESULT 10

ADT77672

ID ADT77672 standard; peptide; 9 AA.

XX

AC ADT77672;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.

XX

OS Homo sapiens.

XX

PN WO2004092213-A1.

XX

PD 28-OCT-2004.

XX

PF 05-APR-2004; 2004WO-US010588.

XX

PR 08-APR-2003; 2003US-0461399P.

XX

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX

PI Pastan I, Bera TK, Lee B;

XX

DR WPI; 2004-758338/74.

XX

PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT encoding nucleic acid molecule for diagnosing, preventing or treating

PT cancer, especially prostate cancer.

XX

PS Disclosure; SEQ ID NO 9; 88pp; English.

XX

CC The present sequence is that of a predicted epitope of human splice
CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC is predicted to bind HLA2-01 and was identified using an HLA binding
CC motif program. It corresponds to amino acids 403-411 of SV-NGEP.
CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC acids of SV-NGEP which specifically bind to an antibody that specifically
CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC claimed. The invention provides methods for: detecting prostate cancer in
CC a subject by contacting a sample with an antibody that specifically binds
CC a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC producing an immune response against a cell expressing SV-NGEP, for
CC example in a subject with prostate cancer, by administering SV-NGEP
CC polypeptide or polynucleotide to produce an immune response that
CC decreases growth of the prostate cancer; inhibiting the growth of a
CC malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC these with the malignant cell; and inhibiting the growth of a malignant
CC cell by contact with an antibody that specifically binds SV-NGEP, where
CC the antibody is linked to a chemotherapeutic agent or toxin.

XX

SQ Sequence 9 AA;

Query Match 1.2%; Score 48; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.9e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 247 WLLSSACAL 255
| | | | | | | |
Db 1 WLLSSACAL 9

RESULT 11

ABJ55714

ID ABJ55714 standard; peptide; 15 AA.

XX

AC ABJ55714;

XX

DT 16-OCT-2003 (first entry)

XX

DE 151P3D4 cancer gene related HLA peptide #13534.

XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.

XX
OS Homo sapiens.
XX
PN WO200283860-A2.
XX
PD 24-OCT-2002.
XX
PF 09-APR-2002; 2002WO-US011644.
XX
PR 10-APR-2001; 2001US-0282739P.
PR 25-APR-2001; 2001US-0286630P.
XX
PA (AGEN-) AGENSYS INC.
XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
DR WPI; 2003-167091/16.
XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.
XX
PS Claim 13; Page 302; 426pp; English.
XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoural or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention
XX
SQ Sequence 15 AA;

Query Match 1.2%; Score 48; DB 6; Length 15;
Best Local Similarity 57.1%; Pred. No. 2e+03;
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFG 469
| | | | : | | | : |
Db 2 RFVGFPDKKHKLYG 15

RESULT 12

ABJ54418

ID ABJ54418 standard; peptide; 15 AA.

XX

AC ABJ54418;

XX

DT 16-OCT-2003 (first entry)

XX

DE 151P3D4 cancer gene related HLA peptide #12238.

XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;

KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;

KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.

XX

OS Homo sapiens.

XX

PN WO200283860-A2.

XX

PD 24-OCT-2002.

XX

PF 09-APR-2002; 2002WO-US011644.

XX

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

XX

PA (AGEN-) AGENSYS INC.

XX

PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;

PI Morrison RK, Ge W, Jakobovits A;

XX

DR WPI; 2003-167091/16.

XX

PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.

XX

PS Claim 13; Page 278; 426pp; English.

XX

CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of

CC the invention
XX
SQ Sequence 15 AA;

Query Match 1.2%; Score 48; DB 6; Length 15;
Best Local Similarity 57.1%; Pred. No. 2e+03;
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFG 469
|||:| | |:|
Db 2 RFVGFPDKKHKLYG 15

RESULT 13

ABJ54982

ID ABJ54982 standard; peptide; 15 AA.
XX
AC ABJ54982;
XX
DT 16-OCT-2003 (first entry)
XX
DE 151P3D4 cancer gene related HLA peptide #12802.
XX
KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoural; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX
OS Homo sapiens.
XX
PN WO200283860-A2.
XX
PD 24-OCT-2002.
XX
PF 09-APR-2002; 2002WO-US011644.
XX
PR 10-APR-2001; 2001US-0282739P.
PR 25-APR-2001; 2001US-0286630P.
XX
PA (AGEN-) AGENSYS INC.
XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
DR WPI; 2003-167091/16.
XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.

XX
PS Claim 13; Page 288; 426pp; English.

XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention

XX
SQ Sequence 15 AA;

Query Match 1.2%; Score 48; DB 6; Length 15;
Best Local Similarity 57.1%; Pred. No. 2e+03;
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFG 469
|||:| | |:|
Db 2 RFVGFPDKKHKLYG 15

RESULT 14
ABJ56325
ID ABJ56325 standard; peptide; 15 AA.
XX
AC ABJ56325;
XX
DT 16-OCT-2003 (first entry)
XX
DE 151P3D4 cancer gene related HLA peptide #14145.
XX
KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX
OS Homo sapiens.
XX
PN WO200283860-A2.
XX
PD 24-OCT-2002.
XX
PF 09-APR-2002; 2002WO-US011644.
XX
PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.
XX
PA (AGEN-) AGENSYS INC.
XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
DR WPI; 2003-167091/16.
XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.
XX
PS Claim 13; Page 313; 426pp; English.
XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention
XX
SQ Sequence 15 AA;

Query Match 1.2%; Score 48; DB 6; Length 15;
Best Local Similarity 57.1%; Pred. No. 2e+03;
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 456 RFVGYPGNYHTLFG 469
|||:| | |:|
Db 2 RFVGFPDKKHKLYG 15

RESULT 15
ABJ56284
ID ABJ56284 standard; peptide; 15 AA.
XX
AC ABJ56284;
XX
DT 16-OCT-2003 (first entry)
XX
DE 151P3D4 cancer gene related HLA peptide #14104.
XX

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX
OS Homo sapiens.
XX
PN WO200283860-A2.
XX
PD 24-OCT-2002.
XX
PF 09-APR-2002; 2002WO-US011644.
XX
PR 10-APR-2001; 2001US-0282739P.
PR 25-APR-2001; 2001US-0286630P.
XX
PA (AGEN-) AGENSYS INC.
XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
DR WPI; 2003-167091/16.
XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.
XX
PS Claim 13; Page 313; 426pp; English.
XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention
XX
SQ Sequence 15 AA;

Query Match 1.1%; Score 47; DB 6; Length 15;
Best Local Similarity 57.1%; Pred. No. 2.5e+03;
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 457 FVGYPGNYHTLFGV 470
|||:| | |:|

Db 1 FVGFPDKKHKLYGV 14

Search completed: June 24, 2008, 15:40:57

Job time : 328 secs

SCORE 3.6